Sage Therapeutics, Inc. - Common Stock (SAGE)

Competitors to Sage Therapeutics, Inc. - Common Stock (SAGE)

Axovant Gene Therapies Ltd.

Axovant Gene Therapies is focused on developing innovative gene therapies for neurological diseases, which overlaps with Sage's focus on central nervous system disorders. Both companies are engaged in advancing therapeutic options for depression and other psychiatric conditions. However, Axovant has a strong emphasis on gene therapies, which may give it a technological advantage over Sage in certain areas of treatment innovation.

H. Lundbeck A/S

H. Lundbeck A/S is a global pharmaceutical company specializing in brain diseases. They compete with Sage Therapeutics by offering alternative treatment options for major depressive disorders and schizophrenia. Lundbeck’s extensive experience and established portfolio of psychiatric drugs provide it with a significant competitive advantage, as they have more resources for clinical development and market entry strategies than Sage.

Intra-Cellular Therapies, Inc. 

Intra-Cellular Therapies develops drugs for neuropsychiatric diseases, competing directly with Sage Therapeutics in the realm of treatments for mood disorders and schizophrenia. Both companies invest heavily in R&D for psychiatric conditions, but Intra-Cellular has a stronger foothold in clinical trials and a promising FDA-approved treatment, providing them with a stronger market position relative to Sage.

Karuna Therapeutics, Inc.

Karuna Therapeutics is focused on developing novel therapies for neuropsychiatric conditions, particularly schizophrenia. Their innovative approach and recent advancements in clinical trials position them as a significant competitor to Sage. Although both companies have overlapping targets, Karuna’s novel treatment strategies, including their unique drug candidates, give them a noteworthy competitive advantage in attracting investor interest and potential partnerships.

Neurocrine Biosciences, Inc. 

Neurocrine Biosciences focuses on developing treatments for neurological and endocrine diseases, much like Sage Therapeutics. Both companies are vying for leadership in the neurology space, especially with psychiatric indications. Neurocrine’s therapeutic pipeline, which includes products directed at movement disorders and psychiatric conditions, gives it a competitive edge in securing FDA approvals for novel treatments sooner due to its established market presence and partnerships.